Learn more about
initial monotherapy
with MIRAPEX
Click here
Download and print
copies of clinical tools
Click here
Learn more about the
symptoms and diagnosis
of Parkinson's disease
Click here

FOR THE INITIAL AND LONG-TERM TREATMENT OF PARKINSON'S DISEASE (PD)

References

  • The Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease. A 4-year randomized controlled trial. Arch Neurol. 2004;61:1044-1053.
  • Pinter MM, Pogarell O, Oertel WH. Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: a double blind, placebo controlled, randomised, multicentre study. J Neurol Neurosurg Psychiatry. 1999;66:436-441.
  • Möller JC, Oertel WH, Köster J, et al. Long-term efficacy and safety of pramipexole in advanced Parkinson's disease: results from a European multicenter trial. Mov Disord. 2005;20:602-610.
  • Shannon KM, Bennett JP Jr, Friedman JH, for the Pramipexole Study Group. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. Neurology. 1997;49:724-728.
  • Barone P, Bressman S. Pramipexole without levodopa as early treatment for Parkinson's disease: a long-term follow-up of 717 patients. Poster presented at: 53rd Meeting of the Annual American Academy of Neurology; May 5-11, 2001; Philadelphia, Pa.
  • Lieberman A, Ranhosky A, Korts D. Clinical evaluation of pramipexole in advanced Parkinson's disease: results of a double-blind, placebo-controlled, parallel-group study. Neurology. 1997;49:162-168.
  • Pogarell O, Gasser T, van Hilten JJ, et al. Pramipexole in patients with Parkinson's disease and marked drug resistant tremor: a randomised, double blind, placebo controlled multicentre study. J Neurol Neurosurg Psychiatry. 2002;72:713-720.
  • IMS Health, National Prescription Audit (NPA) and Next Generation Prescription Services (NGPS), 1997-December 2007.
  • Verispan Managed Care Formulary Drug Audit. Spring 2007.
  • Avalere Health PDP Analysis, October 2006.
  • NINDS Parkinson's Disease Information Page. National Institute of Neurological Disorders and Stroke Web Site. http://www.ninds.nih.gov/disorders/parkinsons disease/detail parkinsons disease.htm. Accessed February 13, 2008.
  • Young R. Update on Parkinson's disease. Am Fam Physician. 1999:59:2155-2167;2169-2170. http://www.aafp.org/afp/990415ap/2155.html.
  • Fahn S. Description of Parkinson's disease as a clinical syndrome. Ann NY Acad Sci. 2003:991:1-14.
  • Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. JAMA. 2000;284:1931-1938.
  • Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology. 2001;56(suppl 5):S1-S88.
  • Adler CH, Sethi KD, Hauser RA, et al, for the Ropinirole Study Group. Ropinirole for the treatment of early Parkinson's disease. Neurology. 1997;49:393-399.
  • Barone P, Bravi D, Bermejo-Pareja F, et al, and the Pergolide Monotherapy Study Group. Pergolide monotherapy in the treatment of early PD: a randomized, controlled study. Neurology. 1999;53:573-579.
  • Rascol O, Brooks DJ, Korczyn AD, et al, for the 056 Study Group. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med. 2000;342:1484-1491.
  • Olanow CW, Stocchi F. Why delaying levodopa is a good treatment strategy in early Parkinson's disease. Eur J Neurol. 2000;7(suppl 1):3-8.
  • MIRAPEX® (pramipexole dihydrochloride) Prescribing Information.
  • Pinter MM, Rutgers AW, Hebenstreit E. An open-label, multicentre clinical trial to determine the levodopa dose-sparing capacity of pramipexole in patients with idiopathic Parkinson's disease. J Neural Transm. 2000;107:1307-23.
  • National Parkinson's Foundation. Living with Parkinson's disease.
  • National Institute of Neurological Disorders and Stroke. Parkinson's disease backgrounder. Available at: http://www.ninds.nih.gov/disorders/parkinsons_disease/parkinsons_disease_backgrounder.htm. Accessed 12/06/06.
  • Wynalda MA, Wienkers LC. Assessment of potential interactions between dopamine receptor agonists and various human cytochrome P450 enzymes using a simple in vitro inhibition screen. Drug Metab Dispos. 1997;25:1211-1214.
  • Waters CH. Diagnosis and Management of Parkinson's Disease.
    2nd ed. Caddo, OK: Professional Communications, Inc; 1999.
  • Michalets EL. Update: clinically significant cytochrome P-450 drug interactions. Pharmacotherapy. 1998;18:84-112.
  • Data on file, Boehringer Ingelheim Pharmaceuticals, Inc.
  • Woodwell DA, Cherry DK. National Ambulatory Medical Care Survey: 2002 Summary. Advance data from vital and health statistics; 346. Hyattsville, MD: National Center for Health Statistics. August 26, 2004.
  • Safran DG, Neuman P, Schoen C, et al. Prescription drug coverage and seniors: findings from a 2003 national survey. Health Affairs [Web exclusive]. April 19, 2005:W5-152-W5-166.
  • Veazey C, Aki SOE, Cook KF, Lai EC, Kunik ME. Prevalence and treatment of depression in Parkinson's disease. J Neuropsychiatry Clin Neurosci. 2005;17:310-323.
  • Verispan.
  • Avalere Formulary, January 2006.
  • National Parkinson Foundation. http://www.parkinson.org/NETCOMMUNITY/Page.aspx?pid=228&scrid=201.
  • Leiberman A. 100 Questions & Answers about Parkinson disease. Sudbury, MA:Jones and Bartlett; 2003.
  • Seibyl JP, Scanley E, Krystal JH, et al. Neuroimaging methodologies. In: Charney DS, Nestler EJ, Bunney BS, eds. Neurobiology of Mental Illness. New York, NY. Oxford University.
 

Important Information about MIRAPEX: MIRAPEX is indicated for the treatment of the signs and symptoms of idiopathic Parkinson’s disease (PD).

Patients have reported falling asleep without perceived warning signs during activities of daily living, including operation of a motor vehicle, which sometimes resulted in accidents. Hallucinations and postural (orthostatic) hypotension may occur. In clinical trials for early PD, the most commonly reported side effects of MIRAPEX that were more frequent than with placebo are nausea (28% vs. 18%), dizziness (25% vs. 24%), somnolence (22% vs. 9%), insomnia (17% vs. 12%), asthenia (14% vs. 12%), and constipation (14% vs. 6%). In clinical trials for advanced PD, the most commonly reported side effects of MIRAPEX that were more frequent than with placebo are postural hypotension (53% vs. 48%), dyskinesia (47% vs. 31%), extrapyramidal syndrome (28% vs. 26%), insomnia (27% vs. 22%), dizziness (26% vs. 25%), accidental injury (17% vs. 15%), hallucinations (17% vs. 4%), and dream abnormalities (11% vs. 10%).

Patients and caregivers should be informed that impulse control disorders and compulsive behaviors have been reported in patients taking dopamine agonists, including MIRAPEX.

Please see full Prescribing Information.

This information is intended for U.S. residents only.